Astellas/Cardiome’s Vernakalant Wins Advisory Committee Approval In 6-2 Vote
Antiarrhythmic’s well-characterized safety profile is a “clear differentiator from other pharmacological therapies,” Astellas exec tells “The Pink Sheet” DAILY.
Antiarrhythmic’s well-characterized safety profile is a “clear differentiator from other pharmacological therapies,” Astellas exec tells “The Pink Sheet” DAILY.